ORMP Stock — Oramed Pharmaceuticals Inc.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 19, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 18.2 · elevated Equity put/call 0.71

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +22%

above

Price vs 50-day avg +1%

above

RSI (14) 51

neutral

MACD trend Negative

52-week position 69%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −11%

trailing

6-month return +23%

trailing

YTD return +57%

this year

Relative strength +15%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $4 › 200d $3 — 50d above 200d

Institutional flow Accumulating

10 of 64 funds reported for Jun 30 · net +23.3K sh shares · +3 new

Insider flow Distributing

Net -$942.2K over 90 days · 100% sells

Short interest Falling

1.87% of float · ▼ -12.8% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

64 holders — near 3-yr high, broad support

Squeeze score 43

elevated · 0–100

Fundamentals

Excellent

Revenue growth +49%

Y/Y

Gross margin 1%

EPS growth +413%

Y/Y

Free cash flow $-9.2M

Valuation P/E 1.6

below peers

Buyback $469.0K

authorized

Balance sheet $45.9M

net cash

Quant / Vol

risk profile

Very High

Volatility 54%

annualized · 1-yr

Max drawdown −24%

past year

ATR 5.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+22% Bullish

Price vs 50-day avg

+1% Bullish

RSI (14)

51 Neutral

MACD trend

Negative Bearish

52-week position

69% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $4 › 200d $3 — 50d above 200d

Institutional flow Accumulating

10 of 64 funds reported for Jun 30 · net +23.3K sh shares · +3 new

Insider flow Distributing

Net -$942.2K over 90 days · 100% sells

Short interest Falling

1.87% of float · ▼ -12.8% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

64 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $2 Now $4 · 69% 52-wk high $5

vs 200-day avg +22% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ORMP Oramed Pharmaceuticals Inc. this stock	$170.66M	+56.9%	—	1.6	1.9%
ONC BeOne Medicines Ltd.	$474.96B	+8.8%	+22179.2%	966.6	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$124.46B	+8.2%	+46.2%	29.1	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$72.88B	-9.8%	+20.8%	17.0	3.3%
ARGX Argenx SE	$54.57B	+3.7%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 32.4%
Reported: 10 of 64
Top holder: BML Capital Management, L…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

765.4K

Days to cover: 2.5d
Change: -112.5K sh

View

Short Volume

Short vol %

53%

As of: Jul 28, 2026

Short Total

View

Fails to Deliver

FTD shares

11.9K

Value: $55.0K
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

48.0%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$942.2K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Sell

Member

Brad Knott

Amount: $15.0K–$50.0K
Traded: Jan 10, 2025

View

Financials

Revenue (FY)

$2.0M

Net income (FY): $64.1M
EPS diluted: $1.50

View

Buybacks

Authorized

$469.0K

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 30, 2026
This year: 7

View

Proposed Sales

Value

$659.0K

Shares: 137.0K
Filed: Jul 1, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ORMP	+1.7%	-10.7%	+22.7%	-13.3%	+57.0%
SPY	-1.0%	0.0%	+7.4%	-0.8%	+8.6%
vs SPY	+2.7%	-10.7%	+15.2%	-12.5%	+48.3%

Capital returns

Latest dividend

$0.25 / share · ex Jan 16, 2026

Paid (TTM)

$0.25 / share · 1 payout

Dividend yield (TTM, derived)

— · history filling in

Buyback program · as of Mar 31, 2026

Authorized

$469,000

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

ORMP · Oramed Pharmaceuticals Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Versus peers

At a glance

Performance

Capital returns